These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 20080645)

  • 1. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.
    Gjerdrum C; Tiron C; Høiby T; Stefansson I; Haugen H; Sandal T; Collett K; Li S; McCormack E; Gjertsen BT; Micklem DR; Akslen LA; Glackin C; Lorens JB
    Proc Natl Acad Sci U S A; 2010 Jan; 107(3):1124-9. PubMed ID: 20080645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.
    Kirane A; Ludwig KF; Sorrelle N; Haaland G; Sandal T; Ranaweera R; Toombs JE; Wang M; Dineen SP; Micklem D; Dellinger MT; Lorens JB; Brekken RA
    Cancer Res; 2015 Sep; 75(18):3699-705. PubMed ID: 26206560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression.
    Goyette MA; Duhamel S; Aubert L; Pelletier A; Savage P; Thibault MP; Johnson RM; Carmeliet P; Basik M; Gaboury L; Muller WJ; Park M; Roux PP; Gratton JP; Côté JF
    Cell Rep; 2018 May; 23(5):1476-1490. PubMed ID: 29719259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
    Holland SJ; Pan A; Franci C; Hu Y; Chang B; Li W; Duan M; Torneros A; Yu J; Heckrodt TJ; Zhang J; Ding P; Apatira A; Chua J; Brandt R; Pine P; Goff D; Singh R; Payan DG; Hitoshi Y
    Cancer Res; 2010 Feb; 70(4):1544-54. PubMed ID: 20145120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma.
    Reichl P; Dengler M; van Zijl F; Huber H; Führlinger G; Reichel C; Sieghart W; Peck-Radosavljevic M; Grubinger M; Mikulits W
    Hepatology; 2015 Mar; 61(3):930-41. PubMed ID: 25251599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
    Dunne PD; McArt DG; Blayney JK; Kalimutho M; Greer S; Wang T; Srivastava S; Ong CW; Arthur K; Loughrey M; Redmond K; Longley DB; Salto-Tellez M; Johnston PG; Van Schaeybroeck S
    Clin Cancer Res; 2014 Jan; 20(1):164-75. PubMed ID: 24170546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer.
    Vuoriluoto K; Haugen H; Kiviluoto S; Mpindi JP; Nevo J; Gjerdrum C; Tiron C; Lorens JB; Ivaska J
    Oncogene; 2011 Mar; 30(12):1436-48. PubMed ID: 21057535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells.
    Asiedu MK; Beauchamp-Perez FD; Ingle JN; Behrens MD; Radisky DC; Knutson KL
    Oncogene; 2014 Mar; 33(10):1316-24. PubMed ID: 23474758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.
    Leconet W; Chentouf M; du Manoir S; Chevalier C; Sirvent A; Aït-Arsa I; Busson M; Jarlier M; Radosevic-Robin N; Theillet C; Chalbos D; Pasquet JM; Pèlegrin A; Larbouret C; Robert B
    Clin Cancer Res; 2017 Jun; 23(11):2806-2816. PubMed ID: 27923843
    [No Abstract]   [Full Text] [Related]  

  • 10. The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target.
    Koorstra JB; Karikari CA; Feldmann G; Bisht S; Rojas PL; Offerhaus GJ; Alvarez H; Maitra A
    Cancer Biol Ther; 2009 Apr; 8(7):618-26. PubMed ID: 19252414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling.
    Wang C; Jin H; Wang N; Fan S; Wang Y; Zhang Y; Wei L; Tao X; Gu D; Zhao F; Fang J; Yao M; Qin W
    Theranostics; 2016; 6(8):1205-19. PubMed ID: 27279912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.
    Mishra A; Wang J; Shiozawa Y; McGee S; Kim J; Jung Y; Joseph J; Berry JE; Havens A; Pienta KJ; Taichman RS
    Mol Cancer Res; 2012 Jun; 10(6):703-12. PubMed ID: 22516347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple roles for the receptor tyrosine kinase axl in tumor formation.
    Holland SJ; Powell MJ; Franci C; Chan EW; Friera AM; Atchison RE; McLaughlin J; Swift SE; Pali ES; Yam G; Wong S; Lasaga J; Shen MR; Yu S; Xu W; Hitoshi Y; Bogenberger J; Nör JE; Payan DG; Lorens JB
    Cancer Res; 2005 Oct; 65(20):9294-303. PubMed ID: 16230391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ΔNp63α Promotes Breast Cancer Cell Motility through the Selective Activation of Components of the Epithelial-to-Mesenchymal Transition Program.
    Dang TT; Esparza MA; Maine EA; Westcott JM; Pearson GW
    Cancer Res; 2015 Sep; 75(18):3925-35. PubMed ID: 26292362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodegradable interstitial release polymer loading a novel small molecule targeting Axl receptor tyrosine kinase and reducing brain tumour migration and invasion.
    Yen SY; Chen SR; Hsieh J; Li YS; Chuang SE; Chuang HM; Huang MH; Lin SZ; Harn HJ; Chiou TW
    Oncogene; 2016 Apr; 35(17):2156-65. PubMed ID: 26257061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA 34a-AXL Axis Regulates Vasculogenic Mimicry Formation in Breast Cancer Cells.
    Lim D; Cho JG; Yun E; Lee A; Ryu HY; Lee YJ; Yoon S; Chang W; Lee MS; Kwon BS; Kim J
    Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
    Byers LA; Diao L; Wang J; Saintigny P; Girard L; Peyton M; Shen L; Fan Y; Giri U; Tumula PK; Nilsson MB; Gudikote J; Tran H; Cardnell RJ; Bearss DJ; Warner SL; Foulks JM; Kanner SB; Gandhi V; Krett N; Rosen ST; Kim ES; Herbst RS; Blumenschein GR; Lee JJ; Lippman SM; Ang KK; Mills GB; Hong WK; Weinstein JN; Wistuba II; Coombes KR; Minna JD; Heymach JV
    Clin Cancer Res; 2013 Jan; 19(1):279-90. PubMed ID: 23091115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axl mediates tumor invasion and chemosensitivity through PI3K/Akt signaling pathway and is transcriptionally regulated by slug in breast carcinoma.
    Li Y; Jia L; Ren D; Liu C; Gong Y; Wang N; Zhang X; Zhao Y
    IUBMB Life; 2014 Jul; 66(7):507-18. PubMed ID: 24984960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axl as a downstream effector of TGF-β1 via PI3K/Akt-PAK1 signaling pathway promotes tumor invasion and chemoresistance in breast carcinoma.
    Li Y; Jia L; Liu C; Gong Y; Ren D; Wang N; Zhang X; Zhao Y
    Tumour Biol; 2015 Feb; 36(2):1115-27. PubMed ID: 25327287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.
    Wu X; Zahari MS; Ma B; Liu R; Renuse S; Sahasrabuddhe NA; Chen L; Chaerkady R; Kim MS; Zhong J; Jelinek C; Barbhuiya MA; Leal-Rojas P; Yang Y; Kashyap MK; Marimuthu A; Ling M; Fackler MJ; Merino V; Zhang Z; Zahnow CA; Gabrielson E; Stearns V; Roa JC; Sukumar S; Gill PS; Pandey A
    Oncotarget; 2015 Oct; 6(30):29143-60. PubMed ID: 26356563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.